Zecotek Receives United States Patent Allowance For Data Acquisition for Positron Emission Tomography Scanner
Singapore, August 14, 2012 – Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the United States Patent Office has issued a Notice of Allowance covering a method of data acquisition for positron emission tomography (PET) scanning devices. Zecotek’s patent portfolio continues to build and strengthen and the Company is emerging as a leading patent holder in the photonics technology space.
“Patents have always been a priority for our Company and they are increasingly playing a strategic role with respect to our business plan as we look to enhance value and create a stronger market position and timely customer adoption,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “Medical imaging is changing at a rapid pace and we are compelled to expand our IP portfolio and secure additional patents associated with our World leading scintillation crystals, solid-state photo detectors and other key components that make up the core of the PET scanners. The granting of a US patent for the data acquisition board and read out electronics strengthens our market position and our potential ability to vertically integrate a new generation of higher performance PET machines; thus offering alternatives for the new emerging economies to manufacture their own scanners through a relationship with Zecotek.”
The data acquisition board and readout system are an important component of PET scanning devices. Zecotek, as a principal financier and a development partner of various imaging components with the University of Washington, radiology department, has the exclusive license rights for a method of data acquisition and design boards to be used in new generation PET scanners.
The data acquisition boards are setup to either digitize analog signals or accept direct digital serial input allowing them to work with any detector design. The list mode acquisition philosophy allows one master set of software to automatically adapt to just about any detector/scanner topology. In addition to this flexibility, if one wants to select different time segments from a study, it can be done after the fact – it does not have to be done as part of the acquisition setup. The flexibility of the system to adapt to different scanner designs means it can support just about any scanner simply by updating the card firmware and mounting on the boards only those components needed. This greatly reduces the engineering costs of starting up a new system.
Zecotek is working with a strategic partner to integrate the three key elements of a PET scanning device: LFS crystals, solid-state MAPD photo detectors and the data acquisition board and readout system. Zecotek has patents or patents pending on each of these key elements and is initiating the integration of a new generation PET scanner configuration for the BRIC (Brazil, Russia, India and China) markets.
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance crystals, photo detectors, medical lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: medical imaging, medical lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. For more information, please visit www.zecotek.com.
This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
For Additional Information Please Contact:
Zecotek Photonics Inc.
T: (604) 783-8291
CHF Investor Relations
Julia Clark, Account Manager
T: (416) 868-1079 x236
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.